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Tyrosine kinase inhibitors (TKIs) are becoming more
important in the management of patients with acute leuke-
mia (AL); however, many questions regarding TKIs remain.
For example, what is the optimal duration of TKI use in
maintenance therapy? We have observed that discontinua-
tion of TKIs leads to a relapse within months in different
types of AL (eg, systemic mastocytosis and an associated
clonal hematologic nonemast cell lineage disease, acute
myelogenous leukemia [AML] with KITD816V mutation,
Philadelphia chromosomeepositive acute lymphoblastic
leukemia [Phþ ALL], and FLT3/ITDþ AML) [1,2]. For each of
these cases should TKI maintenance therapy continue?
When can we declare the patient cured and discontinue
targeted therapy?
These cases are not atypical, and these scenarios are seen
with increasing frequency andmay indicate a challenging yet
exciting era in AL. KITþAML, FLT3/ITDþ AML, and Phþ ALL all
share a poor prognosis because of their expected increased
risk of relapse. Yet each can be targeted by TKI [3]. It is
anticipated that more such entities will be recognized (eg,
BCR-ABLelike ALL, Phþ AML, isocitrate dehydrogenase1 and
2 [IDH1 and IDH2] mutant AML) in the future. It is unlikely
that TKIs can provide extended relapse-free survival as a
single maintenance therapy in patients without allogeneic
hematopoietic cell transplantation (allo-HCT) [4,5] given that
complex molecular genetic aberrations are common [6].
Therefore, for patients with these type of ALdas with other
nonfavorable-risk patientsdallo-HCT is recommendedwhen
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maintenance therapy in these patients [5,8].
Chen et al. [9] showed that sorafenib (a TKI, including FLT3)
maintenance therapy after allo-HCT is feasible. Other small,
relatively short-term studies showed similar results [10,11].
These results are promising and support more advanced clin-
ical studies.However, there is noadequate evidence toguide in
what clinical situation and how long TKIs should be used. For
example, all PhþALL patients receiving a TKI, pre-emptively or
prophylactically, might beneﬁt after allo-HCT [12,13], yet
minimal residual disease (MRD) statuswasnothelpful toguide
maintenance therapy in these patients. Moreover, today the
absence of MRD by current testing (mainly nonstandardized)
cannot be construed as evidence of absolutely no cancer, in
particular ALwith complex geneticmolecular aberrations [14].
MRD testing in most cases cannot distinguish between bulk
disease and those leukemia stem cells that could be respon-
sible for the eventual relapse. Further, leukemia stem cellsmay
be difﬁcult to detect based on their dormancy and/or putative
location in niche locations [15].
Even if the efﬁcacy of TKI maintenance after allo-HCT is
proven, the preferred duration of therapy is unknown. Ample
experience documents that chronic leukemias (chronic my-
elogenous leukemia or chronic lymphocytic lymphoma) may
progress to an acute phase, and such patients may need to be
on therapy of indeﬁnite duration. However, should the same
consideration apply to some subsets of AML patients with a
“targetable mutation” in hematological remission? Approx-
imately 60% of chronic myelogenous leukemia patients with
long and deep responses will relapse in the ﬁrst 12 months
after discontinuation of imatinib [16]; given the available
follow-up, we cannot yet conclude that nonrelapsing pa-
tients are cured with TKI therapy. At present, the only way to
prove the value of extended maintenance therapy is a well-
designed prospective clinical trial with a large number of
patients. Will the availability of effective targeted therapy
allow us to consider some subset of ALs more like their
chronic counterparts?REFERENCES
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